

Ilika Half Year Update

Graeme Purdy, CEO Jason Stewart, CFO

January 2023

Disclaimer

The materials being provided to you in connection with this presentation are strictly confidential and intended only for informational purposes and convenient reference.

This document has been prepared by Ilika plc ("Ilika") and is the responsibility of the same and comprises the written materials for a presentation to investors concerning Ilika.

This information is not intended to provide, and should not be relied upon, for accounting, legal, tax advice or investment recommendations. You should consult your tax, legal, accounting or other professional advisers about the issues discussed herein. The descriptions contained herein are summaries and are not intended to be complete and neither lika nor any of its subsidiaries or affiliates undertakes any obligation to update or correct any errors or inaccuracies in any of the information presented herein. The information in these materials and any other information discussed at the presentation is subject to change.

These materials do not constitute or form part of any offer or invitation to sell or issue or any solicitation of any offer to purchase or subscribe for any securities of lika in any jurisdiction, nor shall it (or any part of it) or the fact of its distribution form the basis of, or be relied upon in connection with, or act as any inducement to enter into, any contract or investment determent.

The distribution of these materials in jurisdictions other than the United Kingdom may be restricted by Jaw and persons into whose possession these materials come should inform themselves about and observe any relevant restrictions. In particular, these materials are not for publication or distribution, distribution, directly or informations, and constitute a violation of such securities laws.

lika has not been, and will not be, registered under the U.S. Investment Company Act of 1940, as amended (the "investment Company Act") and the holders of its shares will not be entitled to the benefits of the investment Company Act. In addition, the offer and sale of the shares mentioned herein have not been, and will not be, registered under the U.S. Investment Cot 1933, as amended (the "investment Company Act.") and the holders of its shares will not be entitled to the benefits of the investment Company Act. In addition, the offer and sale of the shares of like any be offered or sold or otherwise transaction within the transaction referred to in this presentation the shares of like any libe offered and sold only outside the United States to, and for the account or benefit of, non-U.S. persons in "offshore transactions" within the meaning of, and in reliance on the exemption from registration provided by, Regulation S under the Securities Act. No public offer of the shares in the United States and, for the information contained herein does not constitute an offering of securities for sale in the United States. Canada, Australia, New Zealand, South Africa, the Republic of Ireland or Japan. No money, securities or constitute and solicited and, if sent in response to the information contained herein, will not be accepted. Any failure to complex restrictions may constitute a violation of securities laws.

Neither Ilika nor any of its subsidiaries or affiliates makes any representation or warranty, express or implied, as to the accuracy, completeness or verification of the information contained herein, and nothing contained herein shall be relied upon as a promise or representation whether as to past or future performance. In giving this presentation, neither Ilika nor its respective advisers and/or agents undertakes any obligation to provide the recipient with access to any additional information or to update this presentation or any additional information to correct any inaccuracies in any such information may become apparent.

This material is confidential and distribution of this material to any person other than the person to whom this information was originally delivered and to such person's advisers is unauthorised and any reproduction or redistribution of these materials, in whole or in part, or the disclosure of any of their contents, without the prior consent of like or its affiliates is prohibited.

These materials and any offer mentioned herein if subsequently made are only addressed to and directed at persons in member states of the European Economic Area and the United Kingdom who are 'qualified investors' as defined under Regulation (EU) 2017/1129 (the 'Prospectus Regulation'). These materials are for distribution in the United Kingdom only to persons that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the ''Order'); (ii) high net worth entities or other persons falling within Articles 49(2)(a) to (d) of the Order; or (iii) persons to whom it would otherwise be lawful to distribute it (all such persons to even the united Kingdom, relevant persons'). This document or any of its contents. Any investment or investment activity to which this presentation relates is available only to (i) in the United Kingdom, relevant persons.) This document persons. Solicitations: Solicitations: Solicitations: Solicitations: Solicitations: Solicitations: Solicitations: Solicitations: a 'qualified investor'.

These materials include statements that are, or may be deemed to be, "forward-looking statements" which are based on current expectations about future events. In some cases, these forward-looking statements may be identified by the use of forward-looking terminology, including the terms "targets", "believes", "estimates", "anticipates", expects", "intends", "may", "will" or "should" or, in each case, their negative or other variations or comparable common statements may be identified by the use of forward-looking statements segaring the intentions, beliefs or current expectations of like and/or its directors concerning, among other things, the trading performance, results of operations, financial condition, liquidity, prospects and dividend policy of like. By their nature, these forward-looking statements as those included in any other material discussed at any roadshow presentation involve risks and uncertainties because they relate to events and depend on circumstances that may or material discussed at any roadshow presentation involve risks and uncertainties because they relate to events and depend on circumstances that may or material discussed or revise any such forward-looking statements are not guarantees of thure performance. A number of inportant factors could cause actual results or outcomes to differ materially from those expressed, projected or implied in any forward-looking, statements should' to update or revise any such forward-looking statements may not occur. None of the future projections, expectations, estimates or prospects in this presentation should be taken as forecasts or promises or should they be taken as forecasts or promises or roshould be taken as forecasts or promis

Return targets are targets only and are based over the long-term on the performance projections of the investment strategy and market conditions at the time of modelling and are therefore subject to change. There is no guarantee that any target return can be achieved. Investors should not place any reliance on such target return in deciding whether to invest in lika.

To the extent available, the industry, market and competitive position data contained in these materials come from official or third party sources. Third party industry publications, studies and surveys gene contailally state that be data contained in these materials come from official or third party sources. Third party industry publications, studies and surveys gene contails that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness or discusses on to been independently verified, are not comprehensive does independently entitied. The source comprehensive does not been independently entitied, are not comprehensive does not been independently entitied. The source comprehensive does not been independently entitied, are not comprehensive completeness or any of the accuracy or completeness or any of the accuracy or on behalf of lika or any of its directors, officers, employees, agents or advisers or any other person as to the accuracy, completeness of the information, forward-looking statements or opinions or in respect of any omission, and this document is distributed expressly on the basis that it shall not give rise to any liability or obligation if, for whatever reason, any of its contents are or become inaccurate, incomplete or misleading and neither efficiency enciness or the information or to comprehensive does and one to expressive and the source accurace expressive or the completenes or any encines of the information or to completeness or any other expressive and the accuracy or pressive and the accuracy or pressive and the accuracy or any encine of the accuracy or any other expressive and the accuracy or any other expressive of any omission, and this document is distributed expressive of the accuracy or any encine of the accuracy or any

The information and opinions contained in this presentation are provided as at the date of this presentation and are subject to verification, completion and change without notice.

By attending the presentation you agree to be bound by the foregoing limitations.

NOT FOR DISTRIBUTION DIRECTLY OR INDIRECTLY INTO THE UNITED STATES, CANADA, AUSTRALIA, NEW ZEALAND, SOUTH AFRICA, THE REPUBLIC OF IRELAND OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL. THIS COMMUNICATION IS DIRECTED ONLY AT PERSONS TO WHOM IT IS LAWFUL TO COMMUNICATE TO.

Presenting today



Graeme Purdy Chief Executive Officer



- Founding CEO appointed in 2004. Led two VC funding rounds and IPO.
- Previously COO of Avantium BV and early career with Shell International. Latterly NED with Bacanora Lithium plc.
- Chartered engineer with an MEng in Chemical Engineering from Cambridge and an MBA from INSEAD business school in France.

Jason Stewart Chief Financial Officer



- CFO since Jan 2023.
- Previously Interim CFO and other senior roles at Sunseeker International Ltd since 2010. Prior to that at B&Q and Kerry Foods.
- CIMA qualified accountant, with a BSc in Business from Manchester Metropolitan University.

Business overview



llika is one of the few independent global experts in the design and manufacture of solid state batteries



Manufacturing miniature Stereax[®] technology

Developing Goliath solid state pouch cells for consumer appliances and EVs Ultra compact: occupy half the volume of Li-ion, enabling smaller designs

High power density: deliver power pulses for therapy and communication

Safe: no toxic fluid leakage possible










MedTech Applications - Neuromodulation



 Neurostimulators are bioelectronic devices targeting the neural circuits of organs



Implantable Neurostimulators Market \$16bn by 2027, CAGR 11.7% ref





Mm-scale batteries enable miniaturisation in neuromodulation, implanting devices nearer the targeted organs





MedTech Applications – Cardiac Sensing



Cardiovascular diseases are the #1 cause of death globally, taking 17.9M lives each year
Implanted sensors can help with heart failure prevention, and stroke and arrythmia monitoring




Sensors

- Pulmonary heart pressure
- Blood pressure
- Pulse
- Blood oxygen
- Weight
- Symptoms

Miniature batteries enable implantation via catheter





Data wirelessly transmitted to monitor at home or medical practice



Pressure Monitoring Market \$5.5bn by 2027, CAGR 5.5% ref

Cardiac Monitoring (ECG, loop recorders) \$2Bn by 2028, CAGR 9.6% ref



Operational Implementation





1 Section		
		ALC: NO.
	LA	







- Carrying out product qualification and process optimization to increase yield
- Alpha samples of minimum viable product (M300) currently undergoing testing
- Initial orders from 18 customers with deliveries starting Q2/2023













Initial commercial orders from a diverse Medtech customer base

Company Name	Type of Company	Country	Intended Application Area	Sector Size & CAGR	Customer Device SAM* (devices)	Customer Device SOM *
А	Start Up	France	Cardiac/Heart Rhythm	\$7bn/7%	100K's	10K's
В	Multinational (Listed)	USA/Israel	Smart Orthodontics	\$2.5bn/19%	Millions	100K's
С	Multinational (PE Backed)	USA	Implanted Medical Devices	\$2bn/7%	100K's	10K's
D	SME	Israel	Neuromodulation / DBS	\$15bn/12%	100k's	30K
E	Start Up	USA	Implanted Medical Sensor	\$1bn/8%	Millions	100K
F	SME Contracted to Listed Multinational	USA	Smart Orthopaedics	\$8bn/6%	500K	25K
G	Start Up (FAANG owned)	USA	Smart Contact Lens	\$100M/39%	Millions	100K's
Н	Start Up	USA	Smart Contact Lens	\$100M/39%	Millions	100K's
I.	SME Contracted to Listed Multinational	USA	Trauma Screw Mounted Sensor	\$8bn/6%	Millions	100K's
J	Start Up	USA	Smart Dental	\$2.5bn/19%	Millions	80K
К	Government Research Centre	UK	Secure Communications	ТВА	ТВА	ТВА
L	Start Up	USA	Implanted Cancer Sensor	\$1bn/8%	100K's	10K's
Μ	FAANG	USA	ТВА	ТВА	ТВА	ТВА

*Serviceable Addressable/Obtainable Market

Commercial Order Analysis






Pipeline dominated by US Medtech opportunities


Stereax pathway to launch to support MedTech





*Calendar year





MOU signed with Cirtec Medical LLC

- Cirtec Medical: an industry-leading vertically integrated outsource partner for medical devices and components
- Ilika: technology development and IP licensing
- Cirtec: tech transfer to enable manufacturing and commercialization
- Ilika benefits:
 - Further validation of Stereax's capabilities
 - Manufacturing partnership with economy of scale and ability to ramp production
 - Expanded business development resources bringing additional commercial momentum
- Next steps: joint marketing, contract completion and tech transfer







Launched programme for product qualification and process optimization for initial commercial release in Q2 CY23

- Secured 21 initial orders from 18 customers, mainly for medical devices in US
- Signed MOU with Cirtec Medical LLC to transfer manufacturing under license



Ultra compact: occupies half the volume of Liion, enabling smaller designs

High temperature tolerance: reducing pack size and weight

Safe: non-flammable

Environmental benefits: less energy to manufacture and easier to recycle






Market Dynamics






Transport is main contributor of greenhouse gas emissions in UK

(2022 BEIS report ref)



Transport Energy Supply Business Residential Agriculture Others



Technical Readiness





100 Wh/kg achieved

We will be producing cells with targeted dimensions this year (30 cm x 10 cm)



 Trialing processes on production-intent equipment, including Roll-to-Roll








Addressable Sector




Goliath Market Entry Point, addressable market 50 GWh/a




2022 BNEF outlook projects EV sales in 2030 to be 20% higher than 2021 outlook

Passenger EV sales, millions



Scale-up Plan & Business Model







A-samples allow us to enter RFQs

Collaborate to produce B, C samples on production-intent equipment

Commercial Traction



- Met with most of global automotive OEMs, across countries and sectors
- Early participation in RFQs to understand timelines and demand
- Commercial quotes to be issued by Ilika when we hit D4/P1 at the end of 2023
- Two OEMs have signed evaluation contracts in expectation of P1 (first product for customer release) being achieved
- Further partnerships and grant support being pursued.





Increased energy density by 80% over 6 months

- Launched scale-up studies:
 - Equipment design study with COMAU
 - Economic feasibility study with UK-BIC
 - Manufacturing equipment trials

Continued global interaction with automotive and consumer appliance OEMs



Turnover £0.2m (H1 2021/22: £0.2m)

Resulted from grant funding in respect of three ongoing projects.

- EBITDA loss £4.1m (H1 2021/22: £2.7m) Increased operational costs associated with the Stereax manufacturing facility and the Goliath development programme
- Cash balance £18.6m (H1 2021/22: £27.7m) In line with expectations.



Deliver initial batch of Stereax[®] M300 samples H1 CY23 Progress Cirtec relationship through joint marketing, contract completion and technology transfer Mature Goliath technology with partners through defined technical milestones

Commercial opportunity continues to build for Ilika's technology across the large addressable markets providing a strong platform for future growth

Questions



Unit 10a The Quadrangle, Abbey Park Industrial Estate, Romsey SO51 9DL

Tel: +44 (0)23 8011 1400

www.ilika.com